Donanemab Gets FDA Approval
Last month the US Food and Drug Administration (FDA) approved donanemab (Kisunla), for the treatment of early stages of Alzheimer disease. Donanemab is a monoclonal antibody that targets beta-amyloid, one of the abnormal proteins in Alzheimer disease, for removal from the brain. It is administrated intravenously every 4 weeks for 18 months, although it can be discontinued prior to 18 months once amyloid is successfully cleared from the brain. In a recently published clinical trial, donanemab was shown to reduce the progression of cognitive decline and maintain independence in everyday activities. Click to review publication of trial data.
Donanemab joins lecanemab (Leqembi) as the 2nd FDA-approved anti-amyloid antibody treatment approved for Alzheimer disease in the past year. Although the medications have a similar mechanism of action, there are advantages and disadvantages to each.
For more information, click here.
|